R. Références-3, M. Muhlebach, M. Mateo, and P. Sinn, Adherens junction protein nectin-4 is the epithelial receptor for measles virus, Nature, vol.480, pp.530-533, 2011.

Y. Rikitake, K. Mandai, and Y. Takai, The role of nectins in different types of cell-cell adhesion, Journal of Cell Science, vol.125, issue.16, pp.3713-3735, 2012.
DOI : 10.1242/jcs.099572

C. Chan, D. Andrews, and M. Smyth, Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer, Current Opinion in Immunology, vol.24, issue.2, pp.246-51, 2012.
DOI : 10.1016/j.coi.2012.01.009

A. Fuchs and M. Colonna, The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance, Seminars in Cancer Biology, vol.16, issue.5, pp.359-66, 2006.
DOI : 10.1016/j.semcancer.2006.07.002

M. Mateo and M. Lopez, Nectine-4, une prot??ine cl?? pour la transmission du virus de la rougeole, m??decine/sciences, vol.28, issue.4, pp.363-368, 2012.
DOI : 10.1051/medsci/2012284010

Y. Tran, O. Bogler, and K. Gorse, A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer, Cancer Res, vol.59, pp.35-43, 1999.

Y. Murakami, Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis, Cancer Science, vol.165, issue.9, pp.543-52, 2005.
DOI : 10.1093/carcin/bgh055

M. Dewan, N. Takamatsu, and T. Hidaka, Critical Role for TSLC1 Expression in the Growth and Organ Infiltration of Adult T-Cell Leukemia Cells In Vivo, Journal of Virology, vol.82, issue.23, pp.11958-63, 2008.
DOI : 10.1128/JVI.01149-08

S. Nakahata and K. Morishita, CADM1/TSLC1 is a Novel Cell Surface Marker for Adult T-Cell Leukemia/Lymphoma, Journal of Clinical and Experimental Hematopathology, vol.52, issue.1, pp.17-22, 2012.
DOI : 10.3960/jslrt.52.17

S. Fabre-lafay, S. Garrido-urbani, and N. Reymond, Nectin-4, a New Serological Breast Cancer Marker, Is a Substrate for Tumor Necrosis Factor-??-converting Enzyme (TACE)/ADAM-17, Journal of Biological Chemistry, vol.280, issue.20, pp.19543-50, 2005.
DOI : 10.1074/jbc.M410943200

D. Hanahan and L. Coussens, Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment, Cancer Cell, vol.21, issue.3, pp.309-331, 2012.
DOI : 10.1016/j.ccr.2012.02.022

V. Catros-quemener, F. Bouet, and N. Genetet, Immunit?? anti-tumorale et th??rapies cellulaires du cancer, m??decine/sciences, vol.19, issue.1, pp.43-53, 2003.
DOI : 10.1051/medsci/200319143

V. Catros, O. Toutirais, and F. Bouet, Lymphocytes T???? en canc??rologie, m??decine/sciences, vol.26, issue.2, pp.185-91, 2010.
DOI : 10.1051/medsci/2010262185

P. Vantourout and A. Hayday, Six-of-the-best: unique contributions of ???? T cells to immunology, Nature Reviews Immunology, vol.101, issue.2, pp.88-100, 2013.
DOI : 10.1038/nri3384

C. Harly, Y. Guillaume, and S. Nedellec, Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human ???? T-cell subset, Blood, vol.120, issue.11, pp.2269-79, 2012.
DOI : 10.1182/blood-2012-05-430470

S. Vavassori, A. Kumar, and G. Wan, Butyrophilin 3A1 binds phosphorylated antigens and stimulates human ???? T cells, Nature Immunology, vol.87, issue.9, pp.908-924, 2013.
DOI : 10.1158/0008-5472.CAN-06-3069

F. Bouet-toussaint, F. Cabillic, and O. Toutirais, V??9V??2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas, Cancer Immunology, Immunotherapy, vol.20, issue.4, pp.531-540, 2008.
DOI : 10.1007/s00262-007-0391-3

A. Thedrez, V. Lavoue, and B. Dessarthe, A Quantitative Deficiency in Peripheral Blood V??9V??2 Cells Is a Negative Prognostic Biomarker in Ovarian Cancer Patients, PLoS ONE, vol.65, issue.5, p.63322, 2013.
DOI : 10.1371/journal.pone.0063322.s001

V. Lavoue, F. Cabillic, and O. Toutirais, Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of V??9V??2 T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy, International Journal of Cancer, vol.37, issue.Suppl. 2, pp.449-62, 2012.
DOI : 10.1002/ijc.27353

O. Toutirais, F. Cabillic, L. Friec, and G. , DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by V??9V??2 T cells, European Journal of Immunology, vol.199, issue.5, pp.1361-1369, 2009.
DOI : 10.1002/eji.200838409

S. Tahara-hanaoka, K. Shibuya, and Y. Onoda, Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112), International Immunology, vol.16, issue.4, pp.533-541, 2004.
DOI : 10.1093/intimm/dxh059

C. Bottino, R. Castriconi, and D. Pende, Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule, The Journal of Experimental Medicine, vol.9, issue.4, pp.557-67, 2003.
DOI : 10.1016/0092-8674(94)90337-9

B. Dessarthe, A. Thedrez, and J. Latouche, CRTAM Receptor Engagement by Necl-2 on Tumor Cells Triggers Cell Death of Activated V??9V??2 T Cells, The Journal of Immunology, vol.190, issue.9, pp.4868-76, 2013.
DOI : 10.4049/jimmunol.1202596

K. Boles, W. Barchet, and T. Diacovo, The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM, Blood, vol.106, issue.3, pp.779-86, 2005.
DOI : 10.1182/blood-2005-02-0817

L. Galluzzi, I. Vitale, and J. Abrams, Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012, Cell Death and Differentiation, vol.94, issue.1, pp.107-127, 2012.
DOI : 10.1083/jcb.200712051

L. Espert, M. Denizot, and M. Grimaldi, Autophagie et destruction des lymphocytes T CD4 par le VIH-1, m??decine/sciences, vol.22, issue.8-9, pp.677-685, 2006.
DOI : 10.1051/medsci/20062289677

T. Santolaria, M. Robard, and A. Leger, Repeated Systemic Administrations of Both Aminobisphosphonates and Human V??9V??2 T Cells Efficiently Control Tumor Development In Vivo, The Journal of Immunology, vol.191, issue.4, pp.1993-2000, 2013.
DOI : 10.4049/jimmunol.1300255

F. Cabillic, O. Toutirais, and C. De-la-pintière, Aminobisphosphonate-pretreated dendritic cells trigger successful V??9V??2 T cell amplification for immunotherapy in advanced cancer patients, Cancer Immunology, Immunotherapy, vol.157, issue.1, pp.1611-1620, 2010.
DOI : 10.1007/s00262-010-0887-0

L. Martinet, R. Poupot, and J. Fournie, Pitfalls on the roadmap to ???? T cell-based cancer immunotherapies, Immunology Letters, vol.124, issue.1, pp.1-8, 2009.
DOI : 10.1016/j.imlet.2009.03.011

V. Lavoue, A. Thedrez, and J. Leveque, Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer, Journal of Translational Medicine, vol.11, issue.1, p.147, 2013.
DOI : 10.1038/sj.bjc.6605814

URL : https://hal.archives-ouvertes.fr/inserm-00834422

J. Wolchok, H. Kluger, and M. Callahan, Nivolumab plus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.369, issue.2, pp.122-155, 2013.
DOI : 10.1056/NEJMoa1302369